1. Associations of Angiopoietins With Heart Failure Incidence and Severity
- Author
-
Joao A.C. Lima, Samuel G. Rayner, Richard A. Kronmal, Peter J. Leary, David A. Bluemke, Steven M. Kawut, David D. Ralph, Brandon Peplinski, Brian A. Houston, Zachary L. Steinberg, Ryan J. Tedford, and Todd M. Kolb
- Subjects
Adult ,medicine.medical_specialty ,Disease ,030204 cardiovascular system & hematology ,Severity of Illness Index ,Article ,Angiopoietin ,Pathogenesis ,Angiopoietin-2 ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Angiopoietin-1 ,Humans ,030212 general & internal medicine ,Heart Failure ,business.industry ,Incidence (epidemiology) ,Incidence ,Hazard ratio ,Angiopoietins ,medicine.disease ,Cardiovascular Diseases ,Heart failure ,Cohort ,Cardiology ,Cardiology and Cardiovascular Medicine ,business - Abstract
BACKGROUND: Angiopoietin-1 and 2 (Ang1, Ang2) are important mediators of angiogenesis. Angiopoietin levels are perturbed in cardiovascular disease, but it is unclear whether angiopoietin signaling is causative, an adaptive response, or merely epiphenomenon of disease activity. METHODS AND RESULTS: In a cohort free of cardiovascular disease at baseline (MESA), relationships between angiopoietins, cardiac morphology, and subsequent incidence of heart failure or cardiovascular death were evaluated. In cohorts with pulmonary arterial hypertension (PAH) or left heart disease (LHD), associations between angiopoietins, invasive hemodynamics, and adverse clinical outcomes were evaluated. In MESA, Ang2 was associated with a higher incidence of heart failure or cardiovascular death (HR 1.21 per standard deviation, P
- Published
- 2020